Genentech Cathflo Activase is approved
This article was originally published in Pharmaceutical Approvals Monthly
FDA clears tissue plasminogen activator alteplase Sept. 4 for restoring function to occluded central venous access catheters. Genentech's Cathflo Activase will be sold in 2 mg single-use vials, while Activase, indicated for acute MI, acute ischemic stroke and acute massive pulmonary embolism, is sold in 50 and 100 mg vials (Pharmaceutical Approvals Monthly, February 2001, p. 18). The only other product approved for clearing occluded catheters is Abbott's Abbokinase (urokinase), which was pulled from the market in 1999 for GMP deficiencies. Abbott anticipates re-launching its drug in first quarter 2002
You may also be interested in...
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.